期刊文献+

肥大细胞在炎症性肠病发病中的作用机制 被引量:1

Role of mast cells in the pathogenesis of inflammatory bowel disease
下载PDF
导出
摘要 炎症性肠病(inflammatory bowl disease,IBD)是一组反复发作的慢性炎症性肠道疾病,其发病机制并不十分清楚.越来越多的证据表明肥大细胞参与该病的发病.研究发现在IBD患者肠道黏膜中肥大细胞的数量增多了.肥大细胞被各种物质激活释放多种促炎症性细胞因子、化学物质及生物活性介质等在IBD的发生与发展中起重要作用.因此,了解肥大细胞释放的细胞因子和化学介质在IBD中的关键作用有望为治疗这种疾病开拓新的方法. Inflammatory bowel disease (IBD) is a group of recurrent chronic intestinal inflammatory diseas- es with incompletely understood pathogenesis. Increasing evidence has shown that mast cells are markedly increased in inflamed mucosa of IBD patients and involved in the pathogenesis of IBD. Upon activation mast cells release multiple proinflammatory cytokines, chemokines and mediators that play an important role in the oc- currence and development of IBD. Understand- ing the role of mast cell-derived mediators and cytokines in IBD can provide new avenues for the development of new approaches to the treat-ment of this disease.
出处 《世界华人消化杂志》 CAS 北大核心 2013年第7期579-584,共6页 World Chinese Journal of Digestology
基金 国家自然科学基金资助项目 Nos.81070288 81270452 河南省医学科技攻关计划基金资助项目 No.201001004 河南省医学科技学术带头人出国培训计划基金资助项目 No.201201013~~
关键词 炎症性肠病 肥大细胞 炎症介质 Inflammatory bowel disease Mastcells Inflammatory mediators
  • 相关文献

参考文献3

二级参考文献49

  • 1Hanauer SB. Inflammatory bowel disease. N Engl J Med 1996; 334: 841-848.
  • 2Podolsky DK. Inflammatory bowel disease. N Engl J Med 2002; 347: 417-429.
  • 3Rutgeerts P, Van Assche G, Vermeire S. Optimizing anti-TNF treatment in inflammatory bowel disease. Gastroenterol-ogy 2004; 126: 1593-1610.
  • 4Hanauer SB, Feagan BG, Lichtenstein GR, Mayer LF, Sch-reiber S, Colombel JF, Rachmilewitz D, Wolf DC, Olson A, Bao W, Rutgeerts P. Maintenance infliximab for Crohn’s disease: the ACCENT I randomised trial. Lancet 2002; 359: 1541-1549.
  • 5Sands BE, Anderson FH, Bernstein CN, Chey WY, Feagan BG, Fedorak RN, Kamm MA, Korzenik JR, Lashner BA, Onken JE, Rachmilewitz D, Rutgeerts P, Wild G, Wolf DC, Marsters PA, Travers SB, Blank MA, van Deventer SJ. Inflix-imab maintenance therapy for fistulizing Crohn’s disease. N Engl J Med 2004; 350: 876-885.
  • 6Cohen RD, Tsang JF, Hanauer SB. Infliximab in Crohn‘s dis-ease: first anniversary clinical experience. Am J Gastroenterol 2000; 95: 3469-3477.
  • 7Colombel JF, Loftus EV, Tremaine WJ, Egan LJ, Harmsen WS, Schleck CD, Zinsmeister AR, Sandborn WJ. The safety profile of infliximab in patients with Crohn’s disease: the Mayo clinic experience in 500 patients. Gastroenterology 2004;126: 19-31.
  • 8Farrell RJ, Shah SA, Lodhavia PJ, Alsahli M, Falchuk KR, Mi-chetti P, Peppercorn MA. Clinical experience with infliximab therapy in 100 patients with Crohn’s disease. Am J Gastroen-terol 2000; 95: 3490-3497.
  • 9Ricart E, Panaccione R, Loftus EV, Tremaine WJ, Sandborn WJ. Infliximab for Crohn’s disease in clinical practice at the Mayo Clinic: the first 100 patients. Am J Gastroenterol 2001; 96: 722-729.
  • 10Lichtenstein GR, Feagan BG, Cohen RD, Salzberg BA, Dia-mond RH, Chen DM, Pritchard ML, Sandborn WJ. Serious infections and mortality in association with therapies for Crohn‘s disease: TREAT registry. Clin Gastroenterol Hepatol 2006; 4: 621-630.

共引文献55

同被引文献20

  • 1McLean P G,Borman R A,Lee K.5-HT in the enteric nervous system:gut function and neuropharmacology.Trends Neurosci, 2007,30(1):9-13.
  • 2Guilarte M,Santos J,de Torres I,et al.Diarrhoea-predominant IBS patients show mast cell activation andhyperplasia in the jejunum. Gut,2007,56(2):203-209.
  • 3Palsson O S, Mo rteau O,Bozymski E M,et al.Elevatedvaso active intestinal peptide concentrations in patients with irritable bowel syndrome.Dig Dis Sci,2004,49(7 -8): 1236-1243.
  • 4Marchand J E,Sant G R,Kream R M.Increased expression of substance P receptor-encoding mRNA in bladder biopsies from patients with interstitial cystitis.Br J Uro1,1998,81:224-228.
  • 5Pothoulakis C,Castagliuolo I,Leernan S E,et al.Substance P receptor expression in intestinal epithelium in clostridium difficile toxin A enteritis in rats.Am J Physiol,1998,275:G68-G75.
  • 6Keszthelyi D,Troost F J,Jonkers D M,et al.Alterations in mncosal europeptides in patients with irritable bowel syndrome and ulcerative colitis in remission:A role in pain symptom generation? Ettr J Pain,2013.
  • 7Dines K C,Powell H C.Mast cell interactions with the nervous system:relationship to mechanisms of disease.J Neuropathol Ex Neurol, 1997,56:627-640.
  • 8Cast agliuolo L,Lamont J T, Qiu B,et al.Acute stress causesmucin release from rat colon:role of cort icot ropin releasing factorand mast cells.Am J Physiol,1996,271:884-892.
  • 9Palsson O S,Morteau O,Bozymski E M,et al.Elevated vasoactive intestinal peptide concentrations in patients withirritable bowel syndrome.Dig Dis Sci,2004,49(7-8):1236-1243.
  • 10Marchand J E,Sant G R,Kream R M.Increased expression of substance P receptor-encoding mRNA in bladderbiopsies from patients with interstitial cystltis.Br J Urol, 1998,81 (2):224-228.

引证文献1

二级引证文献29

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部